Psilocybin Moves the Social Brain in AUD, And Our Trial Endpoints Are Missing It
A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind...
Amygdala Ultrasound in Depression: What the First Human Data Reveals About Neuromodulation’s Next Frontier
First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, endpoint design, and...
Giredestrant Plus Everolimus Just Cleared the Bar: What the evERA Data Actually Demands From Trial Designers
NEJM publishes evERA Breast Cancer trial data showing giredestrant plus everolimus superiority in HR+ advanced breast cancer, here's what...
The Brain-Wave Trial That Just Raised the Bar for Neuromodulation RCTs
A double-blind tACS trial targeting theta oscillations in methamphetamine patients sets a new design standard regulators will use to...
The AI That Eliminated Cold Chain from mRNA Vaccines Just Changed How You Design a Phase I
AGENT framework achieves 100% mRNA bioactivity after 2+ months at 37°C, forcing a rethink of cold-chain assumptions in vaccine...
The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.
WILLOW Cohort B's p=0.14 masked a 58% BICLA response at the lowest dose. The drug worked. The endpoint couldn't...
The CD47 Signal That Oncology Trial Designers Are Misreading
Evorpacept's Phase 2 data in HER2+ gastric cancer reveals a CD47 biomarker selection gap that could reshape how oncology...
Scaling Clinical AI to One Million Patients Taught Us Things No Pilot Study Could
A Nature Medicine analysis of 1M+ patient AI deployments across three healthcare systems reveals the infrastructure gaps sponsors must...
The EPoS II Trial Just Made the 3-Year Colonoscopy Standard Look Like a Reflex, Not a Rule
EPoS II RCT finds 5-year colonoscopy surveillance noninferior to 3-year for high-risk adenoma patients, forcing a rethink of global...
What the Lancet Psychiatry Mania Data Gets Right, and What It Still Can’t Tell Us
A new target trial emulation in Lancet Psychiatry challenges antipsychotic-first strategies in early psychotic mania. Here's what it means...